Maybelline sales growth revived by Revitalizing line in second quarter.
This article was originally published in The Rose Sheet
Executive SummaryMAYBELLINE REVITALIZING SALES JUMP 54% for the year through June 17 based on A.C. Nielsen data, Maybelline announced in a July 19 release reporting the company's sales and earnings results for the second quarter and first half (ended June 30). The first-half performance of the Revitalizing line represents a turnaround for the brand and for Maybelline as well -- "slower-than-planned" rollout of the product line held back Maybelline sales growth in the third and fourth quarters of last year ("The Rose Sheet" Jan. 30, p. 12)
You may also be interested in...
Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.
Consultant John McKay encourages device makers to ask questions of the US FDA’s inspection team during a facility audit. Check out his advice here.